Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey L. Henken who wrote (2143)	11/13/1998
From: Bill Rogers	Respond to of 2887

#1. I have never worked/sold for a medical distributor, always in sportswear business, my points are strictly from a business, ROI approach. #2. With no money to "educate" ,which someone said is needed, there is no product and relationships with distributors will be short lived. We are still in the better mousetrap stage. #3. If they are only stocking shelves at this time, will there be enough cash for more R&D?? #4. If you don't consider a MRI machine medical technology, Jeff, that is all I need to know about your DD. I am not trying to get into a contest with anyone here, just pointing out that this is going to take a long time. I just ask the hard question...when is this going to perform??? If you don't know, say so and we go unto something else. Have a good week end. Bill

To: Jeffrey L. Henken who wrote (2143)	11/13/1998 12:42:00 AM
From: Ray Tarke	Read Replies (1) \| Respond to of 2887

Jeff I would love to hear your latest due diligence report on those technologies in R&D. Regards, R.T

To: Jeffrey L. Henken who wrote (2143)	11/13/1998 1:25:00 AM
From: Dan A.	Read Replies (1) \| Respond to of 2887

>>Do you feel that ABMI should be valued more on the basis of it's current 100% silicone catheter product line or the potential of those products in R&D? << I'll take a swing at this one..... IMHO, it has to be a little bit of both. Larger companies that are well funded have the luxury of being able to be valued mostly on the potential of their R&D products, since there is significantly less risk in the company going under before the products come to market. In a small company like ABMI, with significant R&D costs, significant debt, and limited marketing capabilities, the basis of their silicone catheter line becomes important in that the sales of their current products may have an impact on their ability to see the R&D projects through to completion. Obviously as we get closer to completion the value increases. There is also an inherrent value of the technology itself, since the patent assets do have a value which can be sold or licensed. The patents' value also increases over time. i.e. A Patent with completed clinical trials, FDA approval and CE Mark is much more valuable that just the patent by itself. I believe that ABMI can make it through to that point, but they have to get current sales up to the break even point (or a cash infusion), so they can stop the share dilution. As my grandfather used to say, "The fastest way to get out of a hole is to stop digging". -Dan P.S. I'd definitely be interested in any new DD info you've dug up.